News AZ, Amgen positive Ph3 results for Tezspire in EoE AstraZeneca and Amgen have announced the first Phase III results for Tezspire (tezepelumab) in eosinophilic oesophagitis (EoE).
News NICE aims to cut funding for Amgen lung cancer drug Lumykras Amgen's Lumykras will no longer be funded by the Cancer Drugs Fund for KRAS-mutated lung cancer, says NHS reimbursement authority NICE.
News Roche's KRAS drug tops its rivals in lung cancer trial Roche has thrown down the gauntlet to Amgen and Bristol Myers Squibb with new phase 3 data for its experimental KRAS G12C inhibitor, divarasib.
News Colorado's pathfinder medicine price-cap move stalls A federal judge in the US has sided with Amgen in a dispute over a price cap imposed by the state of Colorado on blockbuster immunology drug Enbrel.
News FDA clears Viridian's Tepezza rival for thyroid eye disease Viridian has fired a shot across Amgen's bows with the FDA approval of Tepezza rival Lumvoa in thyroid eye disease, a $2bn market.
News EMA advisors say CSL's Tavneos should be pulled from sale Pressure is building on Amgen to withdraw rare disease therapy Tavneos, after the CHMP recommended its marketing authorisation by revoked in the EU.
News ESC26: Isomab safety evidence on blood vessel growth for CAD Isomab has presented landmark safety data at ESC, clearing the path for next-generation therapies to promote blood vessel growth in CAD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
